In Brief: Cardiovascular Diagnostics, Inc.
This article was originally published in The Gray Sheet
Files 510(k) submissions for its Escarin Clotting Time test and Low Range Heparin Management Test. Both tests are based upon CDI's Thrombolytic Assessment System technology, the firm states. The ECT test is intended for use in monitoring the action of Knoll-AG's PEG-Hirudin thrombin inhibitor, for which dosage parameters in the treatment of unstable angina are narrow, the firm explains. The LHMT test is intended for use in measuring heparin levels during cardiac catheterization...
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.